MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Methylthioadenosine phosphorylase (MTAP) gene deletions occur in ~10% of cancers, potentially linked to poor prognosis.
• MTAP deficiency leads to methylthioadenosine (MTA) accumulation, inhibiting protein arginine methyltransferase 5 (PRMT5) activity.
• Previous PRMT5 inhibitors caused significant toxicities due to lack of tumor selectivity.

Purpose of the Study:

• To review novel oncology precision medicines targeting MTAP-deleted cancers.
• To summarize mechanisms, preclinical, and clinical data for PRMT5 pathway inhibitors.
• To discuss future directions for MTAP deletion as a synthetic lethal target.

Main Methods:

• Review of existing literature on MTAP deletion and PRMT5 pathway inhibitors.
• Analysis of preclinical and clinical data for MTA-cooperative PRMT5 inhibitors (e.g., BMS-986504/MRTX1719, AMG 193).
• Evaluation of data for methionine adenosyl transferase 2A (MAT2A) inhibitors (e.g., IDE397).

Main Results:

• MTAP-deleted cancer cells exhibit synthetic lethality upon further PRMT5 pathway inhibition.
• MTA-cooperative PRMT5 inhibitors and MAT2A inhibitors selectively target these vulnerabilities.
• Emerging clinical data suggests promise for these targeted therapies.

Conclusions:

• MTAP deletion represents a significant synthetic lethal vulnerability in cancer.
• Novel PRMT5 pathway inhibitors offer a selective approach to treating MTAP-deleted tumors.
• Further research and clinical trials are warranted to optimize these precision medicines.